FDA Expands Use of Abraxane to Advanced Pancreatic Cancer — Physician’s First Watch
FDA Expands Use of Abraxane to Advanced Pancreatic Cancer
By Kristin J. Kelley
The chemotherapy drug nanoparticle albumin-bound paclitaxel (brand name, Abraxane) is now approved for metastatic pancreatic cancer, the FDA announced late last week. The drug, previously approved for both breast and lung cancers, should be used in combination with gemcitabine.
In a randomized study of some 860 patients, those who received Abraxane plus gemcitabine lived an average of 1.8 months longer than those given gemcitabine alone.
Pneumonitis and sepsis were among the potentially serious side effects of Abraxane plus gemcitabine.